Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD) : Toward a New Age José A. Crippa, Francisco S. Guimaraes, Alline C. Campos, Antonio W. Zuardi Frontiers in Immunology, 21 september 2018. https://doi.org/10.3389/fimmu.2018.02009 Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experimental and clinical use of cannabidiol CBD in neuropsychiatry. Methods: A non-systematic search was performed for studies dealing with therapeutic applications of CBD, especially performed by Brazilian researchers. Results: CBD was shown [...]
Lire la suiteLong-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US Tristan T. Sands, Shahryar Rahdari, Michael S. Oldham, Eduardo Caminha Nunes, Nicole Tilton & Maria Roberta Cilio CNS Drugs, 2018 DOI : 10.1007/s40263-018-0589-2 Abstract Background : Purified cannabidiol is a new antiepileptic drug that has recently been approved for use in patients with Lennox–Gastaut and Dravet syndromes, but most published studies have not extended beyond 12–16 weeks. Objective : The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy. Methods : Patients aged 1–17 years with refractory epilepsy were enrolled in an open-label [...]
Lire la suiteCannabis‐based products for pediatric epilepsy : A systematic review Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth K. Potter, Becky Skidmore, Christine Alexander, Alexander E. Repetski, Vijay Shukla, Bláthnaid McCoy, George A. Wells, Epilepsia, 2018, 1-14. DOI: 10.1111/epi.14608 Summary Objective : To assess the benefits and harms of cannabis‐based products for pediatric epilepsy. Methods : We identified in this living systematic review randomized controlled trials (RCTs) and nonrandomized studies (NRSs) involving children with epilepsy treated with cannabis‐based products. We searched MEDLINE, Embase, PsycINFO, Cochrane Library, and gray literature (April 25, 2018). The primary outcome was seizure freedom; secondary outcomes were seizure frequency (total, ≥50% reduction), quality of life, sleep, status epilepticus, death, gastrointestinal adverse [...]
Lire la suiteLes Phyto-cannabinoïdes Non-psychotropes* : Les nouvelles Opportunités d'une plante ancienne.(*NdT : non-stupéfiants) Angelo A. Izzo, Francesca Borrelli, Raffaele Capasso, Vincenzo Di Marzo and Raphael Mechoulam Trends in Pharmacological Sciences - CELL Press, 2009, 30, 10, 515-27. doi: 10.1016/j.tips.2009.07.006. Le Δ9-tetrahydrocannabinol (Δ9THC) se lie aux récepteurs endocannabinoïdes (CB1 et CB2) qui sont activés par les cannabinoïdes endogènes (endocannabinoïdes) et qui sont impliqués dans une large gamme de processus physiopathologiques (exemple: modulation de la libération de neurotransmetteurs, régulation de la perception de la douleur, régulation des fonctions cardiovasculaires, gastro-intestinales et hépatiques). Les effets psychotropes bien connus du Δ9THC qui sont véhiculés par l'activation des récepteurs CB1 [...]
Lire la suiteRandomized, dose-ranging safety trial of cannabidiol in Dravet syndrome, Orrin Devinsky et al., 2018
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome Orrin Devinsky, Anup D. Patel, Elizabeth A. Thiele, Matthew H. Wong, Richard Appleton, Cynthia L. Harden, Sam Greenwood, Gilmour Morrison, and Kenneth Sommerville, On behalf of the GWPCARE1 Part A Study Group Neurology® 2018, 0:e1-e8. doi:10.1212/WNL.0000000000005254 Abstract Objective : To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. Methods : Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial comprised 4-week baseline, 3-week treatment (including titration), 10-day taper, and 4-week follow-up periods. Completers [...]
Lire la suiteA Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. G. Morrison, J. Crockett, G. Blakey, K. Sommerville Clinical Pharmacology in Drug Development, 2019, PMID : 30791225, DOI : 10.1002/cpdd.665 Abstract GW Pharmaceuticals' formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged ≥2 years, for which clobazam, stiripentol, and valproate are commonly used antiepileptic drugs. This open-label, fixed-sequence, drug-drug interaction, healthy volunteer trial investigated the impact of cannabidiol on steady-state pharmacokinetics of clobazam (and N-desmethylclobazam), stiripentol, and valproate; [...]
Lire la suiteCannabidiol (CBD) : analyse de situation Frank ZOBEL, Luca NOTARI, Eva SCHNEIDER, Ocyna RUDMANN Addiction Suisse, Lausanne, janvier 2019 Rapport de recherche N° 97 https://www.addictionsuisse.ch/fileadmin/user_upload/DocUpload/Rapport-CBD-final.pdf Table des matières Liste des tableaux Liste des graphiques 1 Introduction 2 Méthode 3 Brève analyse de la littérature sur les effets du Cannabidiol (CBD) 3.1 Méthode 3.2 Usages du CBD et effets 3.3 Pourquoi prendre du CBD? Amélioration de la qualité de vie/réduction de certains symptômes dans le domaine somatique Amélioration de la qualité de vie/réduction de certains symptômes dans le domaine psychique Traitement/prévention de maladies chroniques et neurodégénératives, renforcement du système immunitaire . Traitement de troubles neurologiques diagnostiqués . Autres 3.4 Que sait-on de ces effets à ce jour? 3.5 Le CBD peut-il [...]
Lire la suitehttps://www.ncbi.nlm.nih.gov/books/NBK425767/ The Health Effects of Cannabis and Cannabinoids The Current State of Evidence and Recommendations for Research National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. Washington (DC): National Academies Press (US); 2017 Jan 12. ISBN-13: 978-0-309-45304-2ISBN-10: 0-309-45304-6 Copyright and Permissions Hardcopy Version at National Academies Press Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for [...]
Lire la suiteBibliographie Cannabinoïdes et Epilepsie Docteur Christian SUEUR, GRECC, septembre 2018. AGUIRRE-VELASQUEZ C.G. : Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with refractory Epilepsy, Hindawi, Neurology Research International, 2017, ID 2985729, 5 p. American Academy of Neurology : Medical marijuana liquid extract may bring hope for children with severe epilepsy, American Academy of Neurology Press, 2015. https://www.aan.com/PressRoom/Home/PressRelease/1364 AMES F.R., CRIDLAND S. : Anticonvulsivant effect of cannabidiol, South Africa Medical Journal, 1986, 69, 1, 14. ANDERSON P. : Positive Topline Results with Cannabidiol (Epidiolex) in Dravet Syndrome, medscape.com/viewarticle/860357_print, 2016 BLAIR R.E., DESHPANDE L.S., De LORENZO R.J. : Cannabinoids : is there [...]
Lire la suite